文献速递神经免疫

依沃布鲁替尼治疗复发型多发性硬化症的安全性和有效性(evolutionRMS1和evolutionRMS2):两项多中心、随机、双盲、活性对照、3期试验

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
PubMed 文献 · Lancet Neurol · 2024-09-19

两项多中心、随机、双盲、双模拟、活性对照3期试验比较依沃布鲁替尼(45 mg每日两次)与特立氟胺(14 mg每日一次)治疗复发型多发性硬化症,共纳入2290例随机分配参与者。主要终点年化复发率两组无显著差异(evolutionRMS1调整RR 1.02,evolutionRMS2调整RR 1.00)。依沃布鲁替尼疗效未优于特立氟胺,且肝脏相关安全性发现不支持其用于复发型多发性硬化症。

要点

  • 依沃布鲁替尼组与特立氟胺组年化复发率无显著差异:evolutionRMS1调整RR 1.02,evolutionRMS2调整RR 1.00。
  • 严重治疗中出现的不良事件发生率依沃布鲁替尼组高于特立氟胺组(7.5% vs 5.6%)。
  • 肝酶升高至少5倍正常上限在依沃布鲁替尼组更常见,尤其在前12周(5.0% vs <1%)。

核心结论

  • 依沃布鲁替尼的疗效未优于特立氟胺,疗效和肝脏相关安全性发现不支持依沃布鲁替尼用于复发型多发性硬化症患者。

研究设计与样本

  • evolutionRMS1和evolutionRMS2是两项在52个国家701个多发性硬化症中心和神经科诊所开展的多中心、随机、双盲、双模拟、活性对照3期试验。
  • 纳入18-55岁复发型多发性硬化症成人(EDSS评分0.0-5.5),按1:1随机分配至依沃布鲁替尼45 mg每日两次加安慰剂每日一次或特立氟胺14 mg每日一次加安慰剂每日两次,均口服、非空腹状态服用。
  • 随机化按地理区域和基线EDSS分层,所有研究工作人员和参与者对研究干预设盲;主要终点为基于裁定合格复发的年化复发率,评估至156周,在完整分析集(所有随机分配参与者)中用负二项模型分析。
  • 主要分析使用2020年6月12日至2023年10月2日收集的2290例随机分配参与者的数据;evolutionRMS1完整分析集1124例(依沃布鲁替尼组560例,特立氟胺组564例),evolutionRMS2完整分析集1166例(每组583例)。
  • evolutionRMS1中女性751例(66.8%)、男性373例(33.1%),evolutionRMS2中女性783例(67.2%)、男性383例(32.8%)。

主要发现

  • evolutionRMS1中年化复发率依沃布鲁替尼组0.15(95% CI 0.12-0.18)vs 特立氟胺组0.14(95% CI 0.11-0.18),调整RR 1.02(95% CI 0.75-1.39),p=0.55。
  • evolutionRMS2中年化复发率依沃布鲁替尼组0.11(95% CI 0.09-0.13)vs 特立氟胺组0.11(95% CI 0.09-0.13),调整RR 1.00(95% CI 0.74-1.35),p=0.51。
  • 任何治疗中出现的不良事件(TEAE)的汇总比例两组相似:依沃布鲁替尼组976/1140(85.6%)vs 特立氟胺组999/1146(87.2%)。
  • 最常见的TEAE为COVID-19(依沃布鲁替尼组223例[19.6%] vs 特立氟胺组223例[19.5%])、丙氨酸氨基转移酶升高(173例[15.2%] vs 204例[17.8%])、天冬氨酸氨基转移酶升高(110例[9.6%] vs 131例[11.4%])和头痛(175例[15.4%] vs 176例[15.4%])。
  • 严重TEAE发生率依沃布鲁替尼组高于特立氟胺组(86例[7.5%] vs 64例[5.6%]);肝酶升高至少5倍正常上限在依沃布鲁替尼组更常见,尤其在前12周(55例[5.0%] vs 9例[<1%])。

临床怎么用

  • 原文结论指出,疗效和肝脏相关安全性发现不支持依沃布鲁替尼用于复发型多发性硬化症患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evobrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown preliminary efficacy in people with relapsing multiple sclerosis in a phase 2 trial. Here, we aimed to compare the safety and efficacy of evobrutinib with the active comparator teriflunomide in people with relapsing multiple sclerosis. METHODS: EvolutionRMS1 and evolutionRMS2 were two multicentre, randomised, double-blind, double-dummy, active-controlled, phase 3 trials conducted at 701 multiple sclerosis centres and neurology clinics in 52 countries. Adults aged 18-55 years with relapsing multiple sclerosis (Expanded Disability Status Scale [EDSS] score of 0·0-5·5) were included. Participants were randomly assigned (1:1) using a central interactive web response system to receive either evobrutinib (45 mg twice per day with placebo once per day) or teriflunomide (14 mg once per day with placebo twice per day), all taken orally and in an unfasted state, with randomisation stratified by geographical region and baseline EDSS. All study staff and participants were masked to the study interventions. The primary endpoint for each study was annualised relapse rate based on adjudicated qualified relapses up to 156 weeks, assessed in the full analysis set (defined as all randomly assigned participants) with a negative binomial model. These studies are registered with ClinicalTrials.gov (NCT04338022 for evolutionRMS1 and NCT04338061 for evolutionRMS2, both are terminated). FINDINGS: The primary analysis was done using data for 2290 randomly assigned participants collected from June 12, 2020, to Oct 2, 2023. 1124 participants were included in the full analysis set in evolutionRMS1 (560 in the evobrutinib group and 564 in the teriflunomide group) and 1166 in evolutionRMS2 (583 in each group). 751 (66·8%) participants were female and 373 (33·1%) were male in evolutionRMS1, whereas 783 (67·2%) were female and 383 (32·8%) were male in evolutionRMS2. Annualised relapse rate was 0·15 (95% CI 0·12-0·18 with evobrutinib vs 0·14 [0·11-0·18] with teriflunomide (adjusted RR 1·02 [0·75-1·39]; p=0·55) in evolutionRMS1 and 0·11 (0·09-0·13 vs 0·11 [0·09-0·13]; adjusted RR 1·00 [0·74-1·35]; p=0·51) in evolutionRMS2. The pooled proportion of participants with any treatment-emergent adverse event (TEAE) was similar between treatment groups (976 [85·6%] of 1140 with evobrutinib vs 999 [87·2%] of 1146 with teriflunomide). The most frequently reported TEAEs were COVID-19 (223 [19·6%] with evobrutinib vs 223 [19·5%] with teriflunomide), alanine aminotransferase increased (173 [15·2%] vs 204 [17·8%]), aspartate aminotransferase increased (110 [9·6%] vs 131 [11·4%]), and headache (175 [15·4%] vs 176 [15·4%]). Serious TEAE incidence rates were higher with evobrutinib than teriflunomide (86 [7·5%] vs 64 [5·6%]). Liver enzyme elevations at least 5 × upper limit of normal were more common with evobrutinib than with teriflunomide, particularly in the first 12 weeks (55 [5·0%] vs nine [<1%]). Three people who received evobrutinib and one who received teriflunomide met the biochemical definition of Hy's law; all cases resolved after discontinuation of treatment. There were two deaths (one in each group), neither related to study treatment. INTERPRETATION: The efficacy of evobrutinib was not superior to that of teriflunomide. Together, efficacy and liver-related safety findings do not support the use of evobrutinib in people with relapsing multiple sclerosis. FUNDING: Merck.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Montalban X, Vermersch P, Arnold DL, et al. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024. PMID: 39307151. doi:10.1016/S1474-4422(24)00328-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。